FDA to lower number of trials required for approval of drugs, other medical products
The FDA plans to allow drug approvals based on a single clinical trial instead of the traditional two. Commissioner Marty Makary stated that this change aims to streamline the approval process while maintaining safety and efficacy standards. Some exceptions will still apply, where two trials may be required.
- FDA will now generally accept a single clinical trial for drug approval instead of the traditional two
- Two trials will still be required in certain (unspecified) cases
- Makary argues a well-designed, controlled single trial can match the statistical power of two trials
- Many drugmakers were already submitting only one pivotal trial, so the policy formalizes existing practice
The FDA is shifting its approach to medical product approvals, moving to allow a single clinical trial instead of the traditional two. FDA Commissioner Marty Makary shared this development, stating that the agency will still require two trials in certain cases, but the standard will now be one trial for most products. This change reflects a growing flexibility within the FDA and acknowledges that many drugmakers have already been submitting only one pivotal trial for approval.
Makary emphasized that a well-designed and controlled single trial can offer the same statistical power as two trials. This decision aims to streamline the approval process, potentially speeding up the introduction of new medical products to the market. However, it also raises questions about maintaining safety and efficacy standards, as the historical requirement of two trials was intended to provide an extra layer of assurance. The FDA's willingness to adapt may affect how drug development strategies are planned moving forward.